Engineered immune cells take on Hard-to-Treat liver cancer

NCT ID NCT06590246

First seen Jan 11, 2026 · Last updated Apr 30, 2026 · Updated 17 times

Summary

This study tests a new treatment called C-CAR031 for people with advanced liver cancer that has not responded to at least two prior therapies. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The goal is to see if this cell therapy is safe and can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hanzhou, Zhejiang, 310003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • ZhongShan Hospital Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.